BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1149 related articles for article (PubMed ID: 26125441)

  • 1. Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.
    Nagaraj AB; Joseph P; Kovalenko O; Singh S; Armstrong A; Redline R; Resnick K; Zanotti K; Waggoner S; DiFeo A
    Oncotarget; 2015 Sep; 6(27):23720-34. PubMed ID: 26125441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-181a-SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer.
    Belur Nagaraj A; Knarr M; Sekhar S; Connor RS; Joseph P; Kovalenko O; Fleming A; Surti A; Nurmemmedov E; Beltrame L; Marchini S; Kahn M; DiFeo A
    Cancer Res; 2021 Apr; 81(8):2044-2055. PubMed ID: 33574092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells.
    Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y
    Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-10 regulates stemness of ovarian cancer stem-like cells by activation of canonical Wnt signaling and can be a target of chemotherapy-resistant ovarian cancer.
    Mariya T; Hirohashi Y; Torigoe T; Tabuchi Y; Asano T; Saijo H; Kuroda T; Yasuda K; Mizuuchi M; Saito T; Sato N
    Oncotarget; 2016 May; 7(18):26806-22. PubMed ID: 27072580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell Lines.
    Schmidtova S; Kalavska K; Liskova V; Plava J; Miklikova S; Kucerova L; Matuskova M; Rojikova L; Cierna Z; Rogozea A; Konig H; Albany C; Mego M; Chovanec M
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capn4 Enhances Osteopontin Expression through Activation of the Wnt/β-Catenin Pathway to Promote Epithelial Ovarian Carcinoma Metastasis.
    Yang X; Sun J; Xia D; Can X; Liu L; Zhang J; Xu H; Du N; Liu W; Shen F; Zhang Z; Sun Y; Xi X
    Cell Physiol Biochem; 2017; 42(1):185-197. PubMed ID: 28535511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SOX8 regulates cancer stem-like properties and cisplatin-induced EMT in tongue squamous cell carcinoma by acting on the Wnt/β-catenin pathway.
    Xie SL; Fan S; Zhang SY; Chen WX; Li QX; Pan GK; Zhang HQ; Wang WW; Weng B; Zhang Z; Li JS; Lin ZY
    Int J Cancer; 2018 Mar; 142(6):1252-1265. PubMed ID: 29071717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Convergence of Wnt and Notch signaling controls ovarian cancer cell survival.
    Bocchicchio S; Tesone M; Irusta G
    J Cell Physiol; 2019 Dec; 234(12):22130-22143. PubMed ID: 31087357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
    Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
    PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.
    Li RN; Liu B; Li XM; Hou LS; Mu XL; Wang H; Linghu H
    Sci Rep; 2017 Aug; 7(1):9285. PubMed ID: 28839145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-219-5p inhibits the proliferation, migration, and invasion of epithelial ovarian cancer cells by targeting the Twist/Wnt/β-catenin signaling pathway.
    Wei C; Zhang X; He S; Liu B; Han H; Sun X
    Gene; 2017 Dec; 637():25-32. PubMed ID: 28890378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the Wnt/β-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer.
    Zhang Z; Cheng L; Li J; Farah E; Atallah NM; Pascuzzi PE; Gupta S; Liu X
    Cancer Res; 2018 Jun; 78(12):3147-3162. PubMed ID: 29700003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy.
    Zhang C; Zhang Z; Zhang S; Wang W; Hu P
    Med Sci Monit; 2017 Jan; 23():266-275. PubMed ID: 28090074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.
    Yoshioka S; King ML; Ran S; Okuda H; MacLean JA; McAsey ME; Sugino N; Brard L; Watabe K; Hayashi K
    Mol Cancer Res; 2012 Mar; 10(3):469-82. PubMed ID: 22232518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
    Shi L; Xi J; Xu X; Peng B; Zhang B
    Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.